We are Sorry, This Page doesn't Exist
Sarepta"s stock is up 11% on positive data from clinical trial for Duchenne treatment
Shares of Sarepta Therapeutics Inc. gained 11.3% in trading on Tuesday after the co.....»»
Vertex to study experimental gene-editing therapy as treatment for sickle cell, beta-thalassemia
Vertex Pharmaceuticals Inc. said Tuesday it plans to pay $1.1 billion to Crispr Therapeutics AG as part of a deal to test an experimental gene-editing therapy for sickle cell disease and transfusion-dependent beta-tha.....»»
PTC Therapeutics announces two-year data from Part 2 of SUNFISH trial
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Seelos Therapeutics completes enrollment in Part 1 of SLS-002 study
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
FDA PDUFA Date for Sarepta Therapeutics Casimersen is February 25, 2021
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Voyager Therapeutics says Neurocrine terminates Parkinson"s part of agreement
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Calliditas Therapeutics to provide data from Part A of NefIgArd study
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
ROCE Insights For Sarepta Therapeutics
During Q3, Sarepta Therapeutics's (NASDAQ:SR.....»»
: Sarepta stock plunges more than 50% after mixed results from drug study
Sarepta Therapeutics Inc. shares lost more than half their value in after-hours trading Thursday, after the company said a drug candidate produced mixed results in a clinical study......»»
Aileron Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
Enrollment completed in the dose optimization part of the ongoing Phase 1b/2 clinical t.....»»
Sarepta, Dyno Therapeutics to develop gene therapy vectors for muscle diseases
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
June 26th Options Now Available For Sarepta Therapeutics (SRPT)
Stock Options Channel.....»»
PTC Therapeutics announces results from part 2 of pivotal FIREFISH study
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Akari Therapeutics stops enrollment in Part B of Phase I/II trial in severe AKC
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Do Hedge Funds Love Sarepta Therapeutics Inc (SRPT)?
Coronavirus is probably the #1 concern in investors’ minds right now. It should be. On February 27th we published this article and pr.....»»
Sarepta Therapeutics Enters Oversold Territory (SRPT)
Dividend Channel.....»»
Sarepta Therapeutics Larger Than S&P 500 Component Marathon Oil
Market News Video.....»»
BofA names Sage Therapeutics, Sarepta top SMID Biotech picks
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Trillium Therapeutics says Part 4 of TT1-621 study is "ongoing"
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Analysts: Roche Partnership Derisks Sarepta Investor Concerns
Sarepta Therapeutics Inc (NASDAQ: SRPT) has entered a partnership with Roche (OTC: Latest Ratings for SRPT.....»»